- Conditions
- Hepatocellular Carcinoma Non-resectable
- Interventions
- Fluorine-18 fluorocholine
- Combination Product
- Lead sponsor
- Queen's Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 530
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioma
- Interventions
- 18F-fluciclovine
- Drug
- Lead sponsor
- James Mountz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pancreatic Cancer
- Interventions
- CyberKnife based stereotactic radiotherapy, Gemcitabine, Fludeoxyglucose (18F) (FDG)
- Device · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Stanford, California • Baltimore, Maryland • New York, New York
- Conditions
- HIV
- Interventions
- Acute Treatment Interruption
- Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Ce
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, Epcoritamab, Etoposide, Fludeoxyglucose F-18, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Rituximab
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Neuroendocrine Tumors
- Interventions
- 68Ga-DOTATOC PET/CT Scan
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 5 Years and older
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Head and Neck Cancer
- Interventions
- intensity modulated radiation therapy, RAD001 (everolimus) + Cisplatin
- Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Childhood Cancer
- Interventions
- fludeoxyglucose F 18, positron emission tomography, computed tomography, magnetic resonance imaging
- Radiation · Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Intestinal FDG Uptake
- Interventions
- Rifaximin
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cancer Diagnosis, Diagnostic Techniques and Procedures, Diagnostic Imaging
- Interventions
- F-18 FDG, Ga-68-DOTA-TATE, Positron Emission Tomography / Computed Tomography (PET/CT) Scan, Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan
- Drug · Device
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Esophageal Cancer, Lung Cancer
- Interventions
- positron emission tomography, fludeoxyglucose F 18
- Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Asthma, Allergies
- Interventions
- Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage, PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
- Biological · Procedure
- Lead sponsor
- Andrew D. Luster, M.D.,Ph.D.
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Biospecimen Collection, Carboplatin, Cabazitaxel, Abiraterone Acetate, Enzalutamide, Lutetium Lu 177 Vipivotide Tetraxetan
- Other · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Chico, California + 91 more
- Conditions
- Colorectal Cancer, Neoplasm of Uncertain Malignant Potential
- Interventions
- DNA methylation analysis, fluorescence in situ hybridization, gene expression analysis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method, biopsy, therapeutic conventional surgery, fludeoxyglucose F 18
- Genetic · Other · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Survey Administration, Ultrahypofractionated Radiation Therapy
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 486 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 211
- States / cities
- Fort Smith, Arkansas • Irvine, California • La Jolla, California + 162 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- Brentuximab vedotin (SGN-35), Doxorubicin HCL, Vinblastine Sulfate, Dacarbazine, Involved-Site Radiation Therapy (ISRT), Interim PET, consolidation volume RT (CVRT)
- Drug · Radiation · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 10
- States / cities
- Duarte, California • Stanford, California • Basking Ridge, New Jersey + 7 more
- Conditions
- Prostate Cancer
- Interventions
- PET/CT, PET/MRI
- Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Type 2 Diabetes
- Interventions
- Maximal ATP Production (ATPmax), Exercise Testing (VO2max), Muscle Biopsy, Adipose Tissue Biopsy, Hyperinsulinemic euglycemic clamp, PET imaging
- Other · Procedure
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Olfactory Neuroblastoma, Esthesioneuroblastoma, Neoplasm of the Nasal Cavity
- Interventions
- Bintrafusp alfa/M7824, Ibuprofen, PET scan, CT scan, Tumor tissue biopsy, Brain MRI, Dotate scan, PET FDG scan, Nuclear bone scan, EKG
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Mild Cognitive Impairment
- Interventions
- [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose), 18 F fluorodeoxyglucose
- Radiation
- Lead sponsor
- Cell>Point LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 5
- States / cities
- Coral Gables, Florida • Decatur, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Prostate Cancer
- Interventions
- F-fluorodeoxyglucose positron emission tomography (FDG PET), prostate-specific membrane antigen positron emission tomography (PSMA PET)
- Diagnostic Test
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- FDG-PET, Pemetrexed, Sirolimus, Vitamin B12, Folic acid tablets, Dexamethasone tablets
- Drug · Dietary Supplement
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland